Device Trial Radar · NCT06917339
Retrospective Analyses of TrakStar Database
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156,000
Planned (sponsor's estimate)
Start
Feb 25, 2025
Primary completion
Dec 2035
Study completion Dec 2035
Sponsor
- Lead sponsor
- NeuroneticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 8, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 5 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.
Conditions
- Depression
- Obsessive-Compulsive Disorder
- Anxiety Depression
Interventions
NeuroStar Advanced TMS Therapy SystemDevice
non-invasive brain stimulation device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in clinical assessment score from baseline to post-treatmentTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neuronetics
Malvern, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.